Compare AbbVie Inc (ABBV) vs Quanta Services Inc (PWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Quanta Services Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Quanta Services Inc trades at $666.12 (market cap $98.56B). The key difference: AbbVie Inc is far larger — about 4.6× Quanta Services Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | PWR | |
|---|---|---|
Market Cap | $449.91B | $98.56B |
Sector | Health | Industrials |
52-Week High | $261.07 | $785.24 |
52-Week Low | $184.85 | $372.50 |
Enterprise Value | $513.38B | $104.51B |
Dividend Yield | 2.72% | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Quanta Services (PWR) trades at $656.79, down 1.72% amid bearish technical signals, though it maintains strong analyst support with 27 buy ratings. The company shows robust revenue growth, reaching $28.48B in 2025, with consistent earnings beats in recent quarters. However, premium valuation metrics including a P/E of 92.46 and EV/EBITDA of 39.58 present challenges. Recent news highlights infrastructure demand drivers but questions valuation sustainability after a 79% yearly gain.
PWR's outlook is supported by record backlog and infrastructure spending tailwinds, but execution risks and high valuation create near-term headwinds. The consensus price target of $842.67 suggests 28% upside potential, though investors must weigh growth prospects against current premium multiples and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
